TalonBCalipGSLeeTA, et al. Trend in tyrosine kinase inhibitor utilization, price, and out-of-pocket costs in patients with chronic myelogenous leukemia. JCO Oncol Pract2021; 17(11): e1811–e1820.
2.
KenzikKMBhatiaRBhatiaS. Expenditures for first- and second-generation tyrosine kinase inhibitors before and after transition of imatinib to generic status. JAMA Oncol2020; 6: 542–546.
3.
MitchellAPTrivediNUGennarelliRL, et al. Are financial payments from the pharmaceutical industry associated with physician prescribing?Ann Intern Med2020; 174: 353–361.
4.
MitchellAPWinnANLundJL, et al. Evaluating the strength of the association between industry payments and prescribing practices in oncology. Oncologist2019; 24(5): 632–639.
5.
InoueKFigueroaJFOravEJ, et al. Association between industry payments for opioid products and physicians’ prescription of opioids: observational study with propensity-score matching. J Epidemiol Commun Health2020; 74(8): 647–654.
6.
ColeALWoodWAJrMulunehB, et al. Comparative safety and health care expenditures among patients with chronic myeloid leukemia initiating first-line imatinib, dasatinib, or nilotinib. JCO Oncol Pract2020; 16: e443–e455.
7.
GreenwayTRossJS. US drug marketing: how does promotion correspond with health value?BMJ2017; 357: j1855.
8.
CareyCLieberEMJMillerS. Drug firms’ payments and physicians’ prescribing behavior in Medicare Part D. J Publ Econ2021; 197: 104402.
9.
MitchellAPWinnANDusetzinaSB. Pharmaceutical industry payments and oncologists’ selection of targeted cancer therapies in medicare beneficiaries. JAMA Intern Med2018; 178: 854–856.
